A requirement to lower the initial valuation of biotech company Cytovac, has made the company terminate its IPO plans. Cytovac will now turn towards venture capital to try and raise sufficient funds. The company is seeking to raise DKK 80-150m.
ⓘ This story was originally featured in our daily Nordic M&A Newsletter - we publish some of the newsletter content with delay through our M&A Newsletter Library
. If you would like more insights on this deal or industry then send us an email at firstname.lastname@example.org